Dr. Mohamedtaki A. Tejani
Claim this profileAdventHealth Orlando
Studies Pancreatic Cancer
Studies Colorectal Cancer
18 reported clinical trials
35 drugs studied
Area of expertise
1Pancreatic Cancer
BRCA1 positive
BRCA2 positive
PALB2 positive
2Colorectal Cancer
Stage III
Stage IV
dMMR positive
Affiliated Hospitals
Clinical Trials Mohamedtaki A. Tejani is currently running
Regorafenib + Pembrolizumab
for Colorectal Cancer
This is a trial of Regorafenib in combination with pembrolizumab for patients with MSI-H colorectal cancer consisting of lead-in phase examining preliminary efficacy and safety, followed by a randomized phase to further examine efficacy.
Recruiting1 award Phase 2
Nivolumab + Standard Treatment
for Stomach and Esophageal Cancer
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Adding nivolumab to ramucirumab and paclitaxel may work better to treat patients with advanced stomach or esophageal cancer.
Recruiting1 award Phase 2 & 320 criteria
More about Mohamedtaki A. Tejani
Clinical Trial Related4 years of experience running clinical trials · Led 18 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Mohamedtaki A. Tejani has experience with
- Nivolumab
- Oxaliplatin
- Paclitaxel
- Fluorouracil
- Carboplatin
- Ipilimumab
Breakdown of trials Mohamedtaki A. Tejani has run
Pancreatic Cancer
Colorectal Cancer
Colon Cancer
Bile Duct Cancer
Pancreatic Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mohamedtaki A. Tejani specialize in?
Mohamedtaki A. Tejani focuses on Pancreatic Cancer and Colorectal Cancer. In particular, much of their work with Pancreatic Cancer has involved BRCA1 positive patients, or patients who are BRCA2 positive.
Is Mohamedtaki A. Tejani currently recruiting for clinical trials?
Yes, Mohamedtaki A. Tejani is currently recruiting for 5 clinical trials in Orlando Florida. If you're interested in participating, you should apply.
Are there any treatments that Mohamedtaki A. Tejani has studied deeply?
Yes, Mohamedtaki A. Tejani has studied treatments such as Nivolumab, Oxaliplatin, Paclitaxel.
What is the best way to schedule an appointment with Mohamedtaki A. Tejani?
Apply for one of the trials that Mohamedtaki A. Tejani is conducting.
What is the office address of Mohamedtaki A. Tejani?
The office of Mohamedtaki A. Tejani is located at: AdventHealth Orlando, Orlando, Florida 32803 United States. This is the address for their practice at the AdventHealth Orlando.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.